Dexmedetomidine in colon cancer surgery:Evaluating its impact and efficacy  

作　　者：Sohan Lal Solanki Jyoti Sharma 

机构地区：[1]Department of Anaesthesiology,Critical Care and Pain,Tata Memorial Hospital,Homi Bhabha National Institute,Mumbai,MH 400012,India [2]Department of Anaesthesiology,All India Institute of Medical Sciences,Bathinda 151001,India

出　　处：《World Journal of Gastrointestinal Surgery》2024年第12期3663-3665,共3页世界胃肠外科杂志（英文）

摘　　要：We present an editorial on an article that highlights the benefits of dexmedeto-midine(Dex)in colon cancer surgeries,which have been thoroughly investigated in the referenced publication involving 117 subjects.Of these patients,59(group A)received Dex before anesthesia induction,while 58(group B)received normal saline.Group A patients demonstrated several advantages over Group B,inclu-ding lower propofol and remifentanil requirements,improved cerebral oxygena-tion as measured by regional cerebral oxygen saturation,better hemodynamic stability,and reduced incidence of postoperative cognitive dysfunction.In addi-tion to its sedative and analgesic effects,Dex decreases the need for other anes-thetic agents and enhances cerebral oxygenation in elderly patients undergoing colorectal surgery.The literature also supports the anti-inflammatory properties of Dex,which can reduce surgical stress and improve postoperative recovery in cancer patients.This editorial focuses on the various benefits of Dex,particularly its role in maintaining hemodynamic stability and facilitating early recovery in cancer patients.

关 键 词：Colon cancer DEXMEDETOMIDINE IMPACT Human studies Animal models In vitro studies 

分 类 号：R735.34[医药卫生—肿瘤]